Bassil A K, Häglund Y, Brown J, Rudholm T, Hellström P M, Näslund E, Lee K, Sanger G J
Neurology & Gastrointestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, UK.
Br J Pharmacol. 2007 Jan;150(1):58-64. doi: 10.1038/sj.bjp.0706969. Epub 2006 Nov 27.
Obestatin, encoded by the ghrelin gene may inhibit gastrointestinal (GI) motility. This activity was re-investigated.
Rat GI motility was studied in vitro (jejunum contractility and cholinergically-mediated contractions of forestomach evoked by electrical field stimulation; EFS) and in vivo (gastric emptying and intestinal myoelectrical activity). Ghrelin receptor function was studied using a GTPgammaS assay and transfected cells.
Contractions of the jejunum or forestomach were unaffected by obestatin 100 nM or 0.01-1000 nM, respectively (P>0.05 each; n=4-18). Obestatin (0.1-1 nM) reduced the ability of ghrelin 1 microM to facilitate EFS-evoked contractions of the stomach (increases were 42.7+/-7.8% and 21.2+/-5.0 % in the absence and presence of obestatin 1 nM; P<0.05; n=12); higher concentrations (10-1000 nM) tended to reduce the response to ghrelin but changes were not statistically significant. Similar concentrations of obestatin did not significantly reduce a facilitation of contractions caused by the 5-HT(4) receptor agonist prucalopride, although an inhibitory trend occurred at the higher concentrations (increases were 69.3+/-14.0% and 42.6+/-8.7% in the absence and presence of 1000 nM obestatin; n=10). Obestatin (up to 10 microM) did not modulate recombinant ghrelin receptor function. Ghrelin increased gastric emptying and reduced MMC cycle time; obestatin (1000 and 30,000 pmol kg(-1) min(-1)) had no effects. Obestatin (2500 pmol kg(-1) min(-1), starting 10 min before ghrelin) did not prevent the ability of ghrelin (500 pmol kg(-1) min(-1)) to shorten MMC cycle time.
Obestatin has little ability to modulate rat GI motility.
由胃饥饿素基因编码的肥胖抑制素可能抑制胃肠(GI)蠕动。对此活性进行了重新研究。
在体外(空肠收缩性以及电场刺激诱发的前胃胆碱能介导的收缩;EFS)和体内(胃排空和肠肌电活动)研究大鼠胃肠蠕动。使用GTPγS分析和转染细胞研究胃饥饿素受体功能。
空肠或前胃的收缩分别不受100 nM或0.01 - 1000 nM肥胖抑制素的影响(每组P>0.05;n = 4 - 18)。肥胖抑制素(0.1 - 1 nM)降低了1 μM胃饥饿素促进EFS诱发的胃收缩的能力(在不存在和存在1 nM肥胖抑制素时,增加分别为42.7±7.8%和21.2±5.0%;P<0.05;n = 12);更高浓度(10 - 1000 nM)倾向于降低对胃饥饿素的反应,但变化无统计学意义。相似浓度的肥胖抑制素并未显著降低5-HT(4)受体激动剂普芦卡必利引起的收缩促进作用,尽管在较高浓度时出现抑制趋势(在不存在和存在1000 nM肥胖抑制素时,增加分别为69.3±14.0%和42.6±8.7%;n = 10)。肥胖抑制素(高达10 μM)未调节重组胃饥饿素受体功能。胃饥饿素增加胃排空并缩短MMC周期时间;肥胖抑制素(1000和30,000 pmol kg(-1) min(-1))无作用。肥胖抑制素(2500 pmol kg(-1) min(-1),在胃饥饿素前10分钟开始)未阻止胃饥饿素(500 pmol kg(-1) min(-1))缩短MMC周期时间的能力。
肥胖抑制素调节大鼠胃肠蠕动的能力较弱。